IDEXX Laboratories said cash provided by operating activities for the 6 months ended June 30, 2025 was $423.7 million, a decrease of $23.2 million compared to the same period in the prior year. Net income of $536.7 million was adjusted for non-cash items of $111.6 million, partially offset by a decrease of $224.5 million from changes in operating assets and liabilities.

1. 01

   IDEXX Laboratories said cash provided by operating activities for the 6 months ended June 30, 2025 was $423.7 million, a decrease of $23.2 million compared to the same period in the prior year. Net income of $536.7 million was adjusted for non-cash items of $111.6 million, partially offset by a decrease of $224.5 million from changes in operating assets and liabilities.

2. 02

   The company said cash used by financing activities for the 6 months ended June 30, 2025 was $496.0 million, compared to $354.3 million in the same period during the prior year, and included repurchases of common stock of $739.0 million and repayment of 2025 Series C Notes of $103.4 million. Net borrowings under the Credit Facility of $329.0 million partially offset this.

3. 03

   As of June 30, 2025, IDEXX Laboratories said outstanding borrowings under the $1.25 billion Credit Facility were $579.0 million, remaining borrowing availability was $669.1 million, and cash and cash equivalents were $164.6 million. Working capital was $138.5 million, down from $332.0 million as of December 31, 2024.

4. 04

   The company said gross profit margin for the quarter ended June 30, 2025 increased by 90 basis points. It cited higher IDEXX VetLab consumable volumes, productivity improvements, and net price realization as offsetting inflationary impacts, while changes in foreign currency exchange rates decreased the margin by approximately 20 basis points.

Key figures

Quarter ended June 30, 2025

Revenue

$1.1B

Operating income

$373M

Net income

$294M

EPS

$3.63

Gross profit

$695M

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.